The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study (CAT-RA)

December 31, 2025 updated by: Katherine P Liao, Brigham and Women's Hospital
Individuals with rheumatoid arthritis (RA) have up to 2x the risk of having a heart attack compared to someone without RA. The goal of this study is to identify biomarkers that can help us do a better job of identifying individuals at risk before they develop symptoms of heart disease and start preventative treatment earlier.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The objective of this study is to test the utility of high sensitivity cardiac troponin (hs-cTn) and coronary artery calcium (CAC) in risk stratifying patients with rheumatoid arthritis (RA) who may benefit from lipid lowering therapy. The population of interest are individuals who would not otherwise be recommended for therapy based on general population risk calculators for heart disease risk.

Study Type

Observational

Enrollment (Estimated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Recruiting
        • Brigham and Womens Hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • Katherine P Liao, MD, MPH

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients with rheumatoid arthritis, age 40- 79 years, with one cardiovascular risk factor and not on a statin or has a contraindication to statin therapy.

Description

Inclusion Criteria:

  • RA diagnosed by a rheumatologist
  • Age 40- 79
  • ≥1 ASCVD risk factor including prediabetes, hypertension, BMI >30, current or history of cigarette smoking

Exclusion Criteria:

  • Patients on a statin or with a contraindication to statin, on a cholesterol absorption inhibitor, or on a PCSK9 inhibitor
  • Patients with diabetes mellitus
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
coronary artery calcium score
Time Frame: Cross-sectional, at baseline
Quantified coronary artery calcium score
Cross-sectional, at baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Brigham and Women's Hospital

Collaborators

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 4, 2024

Primary Completion (Estimated)

March 4, 2028

Study Completion (Estimated)

March 4, 2028

Study Registration Dates

First Submitted

December 31, 2025

First Submitted That Met QC Criteria

December 31, 2025

First Posted (Actual)

January 5, 2026

Study Record Updates

Last Update Posted (Actual)

January 5, 2026

Last Update Submitted That Met QC Criteria

December 31, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024P001981

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Pending IRB approval.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rheumatoid Arthritis (RA

Clinical Trials on high sensitivity cardiac troponin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe